Clinical trial

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-08-19

PhasePHASE2

Study timeline

Study start (actual)2025-08-19Date precision: day

Registry last updated2026-09-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Metastatic Castration-Resistant Prostate Cancerunresolved

Metastatic Hormone Sensitive Prostate Cancerunresolved

Interventions

PrednisoneDRUG · verified · RxNorm: prednisone

PrednisoloneDRUG · verified · RxNorm: prednisolone

abiraterone acetateDRUG · verified · RxNorm: abiraterone acetate

Adrenocorticotropic hormoneDRUG

Sponsors & collaborators

Astellas Pharma Global Development, Inc.lead sponsor

Mapped research locations

SeoulSouth Korea4 BarcelonaSpain2 MilanItaly2 NashvilleTennessee, United States1 MadridSpain1 LondonUnited Kingdom1 ParisFrance1 CincinnatiOhio, United States1 San DiegoCalifornia, United States1 TampaFlorida, United States1 TaipeiTaiwan1 New OrleansLouisiana, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07005154 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.